Background Patient support programmes (PSPs) allow patients with chronic diseases to receive treatment and support at home. This study describes the Connect 360 PSP delivery and impact on patient-reported outcomes, satisfaction and adherence/persistence among benralizumab-treated patients with severe eosinophilic asthma (SEA). Methods A non-interventional retrospective cohort study using data collected during routine care in the Connect 360 PSP. All consenting enrollees (≥18 years) were included in the study. Results 746 patients formed the study cohort. Mean (SD) age was 53.7 (14.5) years on PSP entry; 38.3% were female (38.7% unknown). 79.6% of patients were experienced biological therapy users. Oral corticosteroid (OCS) use was reported in 48.4% of patients at baseline and 34.8% at 48 weeks. 8.2% of patients reported asthma hospitalisation in the previous 6 months at 24 weeks vs 3.0% at 48 weeks. Mean (SD) 6-item Asthma Control Questionnaire (ACQ-6) scores were 2.7 (1.5) at baseline vs 1.6 (1.3) at 48 weeks. Mean (SD) patient satisfaction scores remained high (4.5 of 5 (1.0) at baseline; 4.7 of 5 (0.6) at 48 weeks). 28.3% of patients were considered adherent at 24 weeks, increasing to 98.3% when supplemented with sales/delivery data (sensitivity analysis). Discontinuation from PSP/benralizumab was low at 24 (3.4%/3.0%) and 48 (12.6%/5.8%) weeks. Conclusions Connect 360 PSP achieved high levels of satisfaction and persistence, with indications of positive outcomes including OCS use, hospitalisation and ACQ-6. The study was conducted during COVID-19, so it provides reassurance that patients with SEA receiving benralizumab may be supported safely and effectively at home. All data relevant to the study are included in the article or uploaded as supplemental information.

中文翻译：

---

参加英国 Connect 360 贝那利珠单抗患者支持计划的患者的特征和结果：一项回顾性队列研究

背景 患者支持计划 (PSP) 允许慢性病患者在家接受治疗和支持。本研究描述了 Connect 360 PSP 的交付以及对接受贝那利珠单抗治疗的重度嗜酸性哮喘 (SEA) 患者报告的结果、满意度和依从性/坚持性的影响。方法 使用 Connect 360 PSP 常规护理期间收集的数据进行非干预性回顾性队列研究。所有同意的参与者（≥18 岁）均纳入本研究。结果 746 名患者组成了研究队列。进入 PSP 时的平均 (SD) 年龄为 53.7 (14.5) 岁；38.3% 为女性（38.7% 未知）。79.6% 的患者是有经验的生物疗法使用者。基线时有 48.4% 的患者使用口服皮质类固醇 (OCS)，第 48 周时有 34.8% 的患者使用口服皮质类固醇 (OCS)。24 周时，8.2% 的患者报告在过去 6 个月因哮喘住院，而 48 周时这一比例为 3.0%。6 项哮喘控制问卷 (ACQ-6) 平均 (SD) 基线得分为 2.7 (1.5)，而 48 周时为 1.6 (1.3)。平均 (SD) 患者满意度评分仍然很高（基线时为 5 分中的 4.5 分 (1.0)；48 周时为 5 分中的 4.7 分 (0.6)）。28.3% 的患者在 24 周时被认为坚持治疗，当补充销售/交付数据时，该比例增加至 98.3%（敏感性分析）。PSP/贝那利珠单抗的停药率较低，分别为 24 周 (3.4%/3.0%) 和 48 周 (12.6%/5.8%)。结论 Connect 360 PSP 实现了高水平的满意度和持久性，并显示出积极的结果，包括 OCS 使用、住院治疗和 ACQ-6。该研究是在 COVID-19 期间进行的，因此它让接受贝那利珠单抗的 SEA 患者可以在家中安全有效地获得支持。与研究相关的所有数据都包含在文章中或作为补充信息上传。